Spectral changes in postoperative MRS in high-grade gliomas and their effect on patient prognosis

Folia Neuropathologica

Volumn 47, Issue 1, 2009, Pages 43-49

  Czernicki, Tomasz ^a   Szeszkowski, Wojciech ^a   Marchel, Andrzej ^a   Gołebiowski, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Brain gliomas; Single voxel proton magnetic resonance spectroscopy; Tumour regrowth

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; POSTOPERATIVE PERIOD; PROGNOSIS; TUMOR GROWTH; BRAIN TUMOR; COMPUTER ASSISTED DIAGNOSIS; GLIOMA; MIDDLE AGED; RADIATION INJURY; RADIOTHERAPY; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIATION INJURIES; RADIOTHERAPY;

EID: 65649117767     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Czernicki Z, Horsztyński D, Jankowski W, Grieb P, Walecki J. Malignancy of brain tumors evaluated by proton magnetic resonance spectroscopy (1H-MRS) in vitro. Acta Neurochir Suppl 2000; 76: 17-20.
2. Esteve F, Rubin C, Grand S, Kolodié H, Le Bas JF. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 1998; 40: 279-286.
3. Graves EE, Nelson SJ, Vigneron DB, Verhey L, McDermott M, Larson D, Chang S, Prados MD, Dillon WP. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. Am J Neuroradiol 2001; 22: 613-624.
4. Kamada K, Houkin K, Abe H, Sawamura Y, Kashiwaba T. Differentiation of cerebral radiation necrosis from tumor recurrence by proton magnetic resonance spectroscopy. Neurol Med Chir (Tokyo) 1997; 37: 250-256.
5. Kinoshita K, Tada E, Matsumoto K, Asari S, Ohmoto T, Itoh T. Proton MR spectroscopy of delayed cerebral radiation in monkeys and humans after brachytherapy. Am J Neuroradiol 1997; 18: 1753-1761.
6. Leclerc X, Huisman TA, Sorensen AG. The potential of proton magnetic resonance spectroscopy (H-MRS) in the diagnosis and management of patients with brain tumors. Curr Opin Oncol 2002; 14: 292-298.
7. Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004; 17: 10-20.
8. McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, Dillon WP, Graves EE, Pirzkall A, Nelson SJ. Histopathological validation of three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97: 794-802.
9. Moller-Hartmann W, Herminghaus S, Krings T, Krings T, Marquardt G, Lanfermann H, Pilatus U, Zanella FE. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44: 371-381.
10. Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 2000; 26: 397-409.
11. 99Tc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy. Q J Nucl Med Mol Imaging 2006; 50: 88-93.
12. Rabinov JD, Lee PL, Barker FG, Louis DN, Harsh GR, Cosgrove GR, Chiocca EA, Thornton AF, Loeffler JS, Henson JW, Gonzalez RG. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002; 225: 871-879.
13. Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T. Correlation between magnetic resonance spectroscopy and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2002; 51: 912-920.
14. Shimizu H, Kumabe T, Shirane R, Yoshimoto T. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. Am J Neuroradiol 2000; 21: 659-665.
15. Smith DR, Hardman JM, Earle KM. Metastasizing neuroectodermal tumors of the central nervous system. J Neurosurg 1969; 31: 50-58.
16. Tamiya T, Kinoshita K, Ono Y, Matsumoto K, Furuta T, Ohmoto T. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 2000; 42: 333-338.
17. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, Di Chiro G. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997; 87: 516-524.
18. Wald LL, Nelson SJ, Day MR, Noworolski SE, Henry RG, Huhn SL, Chang S, Prados MD, Sneed PK, Larson DA, Wara WM, McDermott M, Dillon WP, Gutin PH, Vigneron DB. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997; 87: 525-534.
19. Walecki J, Sokół M, Pieniazek P, Maciejewski B, Tarnawski R, Krupska T, Wydmański J, Grieb P. Zastosowanie spektroskopii protonowej MR o krótkim czasie TE w monitorowaniu wczesnych zmian popromiennych. Rez Magn Med 1999; 7: 5-11.
20. Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000; 18: 1020-1026.
21. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572-2578.